GSK3B and pulmonary fibrosis: Ubiquitin editing enzyme 20 (A20) interacts with and inactivates protein kinase glycogen synthase-3β (GSK-3β) and inhibits the degradation of the transcription factors CCAAT and enhancer-binding protein β (C/EBPβ) within alveolar macrophages (AMS), leading to a compliant phenotype of AMS, i.e., the M2 phenotype promotes the pulmonary fibrosis (PF) development 34.